Antimicrobial Drug Consumption on Swiss Pig Farms: A Comparison of Swiss and European Defined Daily and Course Doses in the Field

Thomas Echtermann 1*, Cedric Muentener 2, Xaver Sidler 1 and Dolf Kümmerlen 2

1 Division of Swine Medicine, Department for Farm Animals, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
2 Institute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland

Defined Daily Doses (DDD) and Defined Course Doses (DCD) have been established in both human and veterinary medicine in order to standardize the measurement of treatments in a population. In 2016 the European Medicines Agency published average defined daily dose (DDDvet) and defined course dose (DCDvet) values for antimicrobial agents used in livestock production. Similarly, national defined doses (DDDch and DCDch) for the pig sector in Switzerland have recently been determined. The aim of this study was to compare the outcome of calculating antimicrobial consumption based on either DDDvet/DCDvet or DDDch/DCDch. Data from 227 Swiss pig farms describing antimicrobial use in 2015 was collected. The numbers of treatment days and treatments were calculated using DDDvet/DCDvet and DDDch/DCDch respectively, for each farm in total and for different antimicrobial classes. Associations between calculated numbers of DDDvet/DCDvet and DDDch/DCDch on farm level were investigated. In addition, differences concerning antimicrobial use were investigated between different production types of farms (piglet-producer, finishing farm or farrow-to-finishing farm). Using DDDch/DCDch values we calculated 1,805,494 treatment days and 433,678 treatments compared to 1,456,771 treatment days (19% ratio) and 303,913 treatments (30% ratio) based on DDDvet/DCDvet. Penicillins (21.4/26.6%), polypeptides (18.6/27.6%) and fluoroquinolones (9.5/8.8%) were the most frequently used classes of antimicrobials based on calculation using both DDDvet and DDDvet. Similar findings were observed for complete treatments (DCDch/vet) (penicillins: 52.8/39.6%; polypeptides: 7.8/14.2%; fluoroquinolones: 13.2/12.9%). The number of treatment days or treatments per farm was higher for piglet-producers and farrow-to-finishing farms compared to finisher farms regardless of whether Swiss or European DDD or DCD values were used for the calculation (each \( P < 0.001 \)). Similar results for antimicrobial use (AMU) obtained at farm level were observed when calculated either by Swiss or European definitions. Nevertheless, marked differences could be observed in the assessment of the use of specific antimicrobial classes in the field based on DDDvet/DCDvet compared to DDDch/DCDch.

Keywords: antimicrobial drug usage, antimicrobial classes, defined daily dose, defined course dose, European medicines agency, monitoring systems, pigs, Switzerland
INTRODUCTION

Antimicrobial use (AMU) is associated with the selection of resistant pathogens (1, 2) and the spread of resistance both within and between human and veterinary medicine (3–5). Responsible use of antimicrobials is therefore essential (6).

The importance of antimicrobial resistance for public health is internationally acknowledged (7, 8) and AMU in food-producing animals is monitored by various authorities (9, 10) in order to determine trends in resistance development.

In addition to monitoring systems measuring the amount of active ingredients, systems based on application equivalents have been established in several countries to monitor AMU in veterinary medicine (11–13). These application equivalents, originally developed for humans (14), standardize the measurement of AMU (15), by taking into account the dosages of the various antimicrobial compounds, and defining a dosage required daily or for a whole treatment. In line with the formal definition of the World Health Organization (WHO), Defined Daily Doses (DDD) and Defined Course Doses (DCD) are the assumed average maintenance doses per day or total treatment duration (16), which allow the estimation of number of treatment days respectively, number of treatments in a population (17).

In 2016, following these principles, the European Medicines Agency (EMA) published average defined daily dose (DDDvet) and defined course dose (DCDvet) values for antimicrobial agents used in livestock production as a tool to facilitate standardized collection and presentation of AMU among European member states (18). These values were defined by calculating the mean of given registrations for livestock production from nine different European countries. In analogy with the principles of the EMA (19), national defined doses (DDDch and DCDch) for each individual registration in the pig sector in Switzerland were recently determined and some theoretically discrepancies between Swiss and European values have been described in a prior study (20).

The aim of this study was to investigate the outcome of calculated antimicrobial consumption in the field based on either individual, Swiss values (DDDch/DCDch) or average, European values (DDDvet/DCDvet). The impact of using either DDD/DCDch or DDD/DCDvet values were tested for different age groups, administration routes and antimicrobial classes. Moreover, the impact of using either DDD/DCDch or DDD/DCDvet for evaluation of antimicrobial use on the study farms was considered, as well as differences in antimicrobial usage by farm type.

The questions behind all these investigations were: Will an AMU monitoring system based on either Swiss or European definitions lead to comparable results in the field or not? And for which age groups, administration routes and antimicrobial classes can the most frequent AMU be observed in the pig sector of Switzerland?

MATERIALS AND METHODS

Data Collection

In cooperation with the Swiss Swine Health Service (SSHS), data from 227 Swiss pig farms concerning antimicrobial use in 2015 was collected, thus representing 3.3% of all pig farms in Switzerland in 2015 (21). All 227 farms joined a nationwide voluntary program for pig producers in Switzerland in order to evaluate and improve transparency of AMU on their farms. Only farms with a complete documentation of antimicrobial ingredients purchased in the year 2015 were included in the study. The study farms were required to provide documentation of all veterinary prescriptions of antimicrobials for this year, including exact information about the name and the amount of the used products. Farmers were required to allocate the prescribed antimicrobials to four different groups (sow, finisher pig, weaner, and piglet). The documentation had to be reported once every 3 months during the year. In addition to AMU records, numbers of pigs kept (sows) or produced annually (all other age groups) and the type of farm were also documented. Overall 96 piglet-producing farms, 42 farrow-to-finish pig farms and 89 finishing farms housing a total of 328,909 piglets, 292,298 weaners, 179,144 finishing pigs and 11,710 sows were included in the study. The number of sows were representing 9.5% of all sows kept in Switzerland, which were notified in 2015 (21). The mean farm size was 85 sows with 2,383 produced piglets and 2,108 produced weaners in the year 2015, including the data of all piglet-producing and farrow-to-finish farms. The mean of the produced finishing pigs was 1,303, combined the data of the farrow-finish farms and the finishing farm, respectively. A piglet-producing farm housing at least 30% piglets from birth until time of slaughter was considered as farrow-to-finish farm.

AMU Quantification

In order to quantify AMU, the amount of prescribed antimicrobial ingredient during the year 2015 of all participating farms was divided by the defined doses (DDD/DDDvet or DDC/DDCvet) of the corresponding antimicrobial classes multiplied by the standard weights of the different age groups as defined by the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) (piglets: 4 kg; weaners: 12 kg; finisher pig: 50 kg and sow: 220 kg) (22).

\[
\text{Number of Defined Doses} = \frac{\text{total amount of prescribed antimicrobial ingredient (mg)}}{\text{DDDvet or DDDch or DCDvet or DCDch} \times \text{standard weight of age group (kg)}}
\]
Total and relative antimicrobial use (AMU) on 227 Swiss pig farms in the year 2015.

TABLE 1 | Total and relative antimicrobial use (AMU) measured as active ingredient and by Swiss and European defined dosage grouped by different antimicrobial classes.

| Antimicrobial classes | Amount of active ingredient in kg | DDDch\(^a\) | DDDvet\(^b\) | DCDch\(^c\) | DCDvet\(^d\) |
|------------------------|----------------------------------|-------------|-------------|------------|-------------|
| Aminoglycosides         | 25.7                             | 67.273      | 59.973      | 20.918     | 15.255      |
| Amphenicol             | 0.03                             | 44          | 69          | 22         | 22          |
| Cephalosporins         | 0.3                               | 2,200       | 2,299       | 733        | 636         |
| Fluoroquinolones       | 6.0                               | 171,518     | 127,880     | 57,173     | 39,064      |
| Lincosamides           | 0.7                               | 26,217      | 20,456      | 2,777      | 2,997       |
| Macrolides             | 21.4                              | 293,108     | 120,006     | 33,286     | 15,148      |
| Pencillins             | 77.8                              | 385,507     | 388,221     | 229,006    | 120,394     |
| Pleomucillins          | 4.0                               | 14,388      | 11,289      | 1,188      | 1,623       |
| Polypeptidines         | 26.0                              | 335,498     | 402,708     | 33,687     | 43,006      |
| Pyrimidines            | 2.1                               | 6,613       | 6,252       | 1,653      | 1,705       |
| Sulfonamides           | 144.1                             | 228,817     | 98,192      | 23,946     | 30,848      |
| Tetracyclins           | 113.1                             | 274,311     | 219,426     | 29,289     | 33,215      |

\(^a\)DDDch: Number of treatment days based on Swiss Defined Daily Doses.  
\(^b\)DDDvet: Number of treatment days based on Defined Daily Doses of the European Medicine Agency (EMA).  
\(^c\)DCDch: Number of treatments based on Swiss Defined Course Doses.  
\(^d\)DCDvet: Number of treatments based on Defined Course Doses of the European Medicine Agency (EMA).
was calculated.

\[
\text{Number of Defined Doses per farm} = \frac{\text{total amount of prescribed antimicrobial ingredient per farm and age group (mg)}}{\text{DDDvet or DDDch or DCDvet or DCDch (mg/kg) × standard weight of age group (kg) × number of pigs per farm and age group}}
\]

Data Processing and Statistical Analysis

The preparation of all operating farm data and the calculation of the number of defined doses was carried out using Microsoft Excel 2011 (Microsoft, Redmond, WA, USA). The statistical analysis and preparation of graphs to visualize the results was performed with R (https://cran.r-project.org). Differences between the tested groups having a \( P \leq 0.05 \) were considered statistically significant. The data for calculated AMU on farm level was tested for normality by the Shapiro-Wilk test. The association of Swiss and European dosages for a possible AMU monitoring system on the farms was evaluated using scatterplots and correlation analysis performed by Spearman’s rho test. The differences between the various farm structures were investigated using the Kruskal-Wallis test for independent samples and post hoc pairwise analysis (Bonferroni correction).

RESULTS

AMU Quantification per Age Group and Administration Route

In this study, the AMU was calculated at 1,805,494 DDDch and 433,678 DCDch when based on Swiss values, compared to 1,456,771 DDDvet (−19.3% ratio) and 303,913 DCDvet (−29.9% ratio) based on European defined doses (Table 1). The mean treatment duration was 3.7 days based on Swiss values and 4.0 days based on European values. The largest fraction of DDD was calculated for weaners, regardless of Swiss DDDch (64.4%) or European DDDvet (60.3%), whereas for DCDs based on Swiss definitions, piglets represented the major part of the treatments (53.1%). Based on European definitions most calculated course doses were observed for weaners (44.8%). Ratios of more than 20% between the calculated numbers of DDD/DCDch and

![FIGURE 1](Relative distribution of antimicrobial use (AMU) between different antimicrobial classes measured either as the amount of active ingredient or as the number of defined daily doses (DDD) or defined course doses (DCD), respectively. DDD and DCD were calculated with Swiss values (DDDch and DCDch) or European values (DDDvet or DCDvet) published by the European Medicines Agency (EMA). (Amphenicols and cephalosporins as well as lincosamides are not inscribed due to the low values).)
Tetracyclines were more frequently used when calculating AMU based on defined doses. Contrastingly, when calculating in course doses, injections represented the largest proportion of treatments. Penicillins and aminoglycosides were frequently used injections for finisher pigs and tetracyclines were the most commonly used antimicrobial class given as premix. As was the case in weaners, macrolides represented a considerable proportion of treatments based on DDDch as well as DCDch. In sows, most antimicrobials were given by injections and within this group, most of the antimicrobials administered belonged to the antimicrobial classes of penicillins and fluoroquinolones. The most frequently administered antimicrobial class provided as a premix was the class of penicillins. An administration of oral antimicrobials without feed or water was only observed for fluoroquinolones and polypeptides in piglets and on only two farms with a small amount in weaners.

**AMU Quantification per Antimicrobial Classes**

The amount of active ingredient and the calculated numbers of defined doses for different antimicrobial classes were summarized in Table 2 and the relative distribution was visualized in Figure 1. Considering the amount of active ingredient used, the classes of sulfonamides (144,086,000 mg/34.3%), tetracyclines (113,122,600 mg/26.9%), and penicillins (77,788,850 mg/18.5%) represented the largest proportion of the total usage, whereas when using defined daily doses, penicillins (DDDch: 385,507/21.4%; DDDvet: 388,221/26.6%) and polypeptides (DDDch: 335,498/18.6%; DDDvet: 402,708/27.6%) were the most frequent. Macrolides were observed to represent 16.2% of the total usage (293,108 treatment days) calculated in DDDch. Penicillins (DCDch: 229,006/52.8%; DCDvet: 120,394/39.6%) and fluoroquinolones (DCDch: 57,173/13.2%; DCDvet: 39,064/12.9%) were common for the number of total treatments, as well as polypeptides (DCDvet: 43,006/14.2%) for calculations based on the European values. The percentage of fluoroquinolones in total AMU was 1.4% when considering the amount in mg, compared to 8.8 and 13.2% when calculating DDDvet and DCDch, respectively.

A more detailed, combined consideration of age groups, administration routes, and antimicrobial class data shows that injection was the most frequent administration route for piglets independent of the method used for calculation, and that within this group penicillins and fluoroquinolones were the most frequently used antimicrobials (Table 3). The use of premixes was the most frequently used administration route for weaners independent of the indicator used and polypeptides were most frequently used when considering the number of defined daily doses. For the number of calculated doses based on DDD/DCDch, frequent use of macrolides was notable in the premixes given to weaners whereas sulfonamides and tetracyclines were more frequently used when the calculation was based on DDD/DCDvet. In terms of the finisher pig group, injection and premixes were observed with similar frequencies for administration routes, when either daily doses or course doses were the basis of the calculation. Oral administration of premixes was the most common administration route when calculating AMU based on defined doses. Contrastingly, when calculating in course doses, injections represented the largest proportion of treatments. Penicillins and aminoglycosides were frequently used injections for finisher pigs and tetracyclines were the most commonly used antimicrobial class given as premix. As was the case in weaners, macrolides represented a considerable proportion of treatments based on DDDch as well as DCDch. In sows, most antimicrobials were given by injections and within this group, most of the antimicrobials administered belonged to the antimicrobial classes of penicillins and fluoroquinolones. The most frequently administered antimicrobial class provided as a premix was the class of penicillins. An administration of oral antimicrobials without feed or water was only observed for fluoroquinolones and polypeptides in piglets and on only two farms with a small amount in weaners.

**AMU Monitoring on Farm Level**

Each dataset was tested for normality by Shapiro-Wilk test and for all datasets, independent of Swiss or European measuring method or type of farm, the null hypothesis was rejected (each P < 0.001).

The scatterplot of calculated defined daily doses (DDD) and defined course doses (DCD), analyzing the association between Swiss (ch) and European (vet) definitions, is given in Figure 2. As shown, both the calculated number of daily doses and the calculated number of course doses showed a positive correlation between results on the farm level by Spearman’s rho test.

Consideration of structure of the various farms pointed to a higher amount of calculated AMU per farm and per year on farrow-to-finishing farms and piglet-producing farms compared to finishing farms for all Swiss or European values of defined doses (P < 0.001) by Kruskal-Wallis-test and subsequent post hoc pairwise analysis (Table 4, Figure 3). In terms of calculated DDDch-numbers the median values were 4.40, 4.88, and 0.27 for farrow-to-finishing, piglet-producing and finishing farms, respectively. No significant difference between the farrow-to-finishing farms and the piglet-producers was observed for any of the used values.

**DISCUSSION**

This study shows that although evaluating AMU for the pig sector at the farm level based either on Swiss or European defined doses leads to similar results with a positive correlated association, there were still deviations in detail, i.e., in the assessment of the different active substance classes, different administration routes and various age groups. A possible on farm AMU monitoring system will arrive at similar conclusions and farms with low or high AMU consumption will be similarly assessed using both methods. Since the Swiss definitions are based on individual national approvals in comparison to the average EMA definitions collected from nine countries, the Swiss definitions seem more robust for a national evaluation of active substance classes, administration routes and age groups.

The challenge of collecting adequate information on AMU in the field is well-known and described in the literature (15). Since...
| Age group | Administration route | Antimicrobial classes | Amount of active ingredient in mg | DDDch (n) (%) | DDDvet (n) (%) | CDCch (n) (%) | DDDvet (n) (%) |
|-----------|----------------------|-----------------------|-----------------------------------|---------------|---------------|---------------|---------------|
| Piglets   | Oral                 | Fluoroquinolones      | 15,117,075 473,922                | 428,546       | 230,237       | 132,433       |
|           | Oral                 | Polypeptides          | 118,250 0.8% 138,333              | 230,237       | 132,433       | 132,433       |
|           | Injection             | Aminoglycosides       | 14,764,825 450,340                | 95.0%         | 94.9%         | 97.7%         |
|           | Injection             | Polypeptides          | 47,875 0.1% 880                   | 2.9%          | 2.3%          | 1.9%          |
|           | Injection             | Fluoroquinolones      | 12,458 90.1% 83,050               | 82.5%         | 93.8%         | 93.8%         |
|           | Injection             | Polypeptides          | 1,375 9.9% 1,760                  | 17.5%         | 6.2%          | 14.5%         |
|           | Injection             | Aminoglycosides       | 83,050 70.2% 39,802               | 29.8%         | 17.5%         | 26.8%         |
|           | Injection             | Polypeptides          | 35,200 29.8% 1,375                | 17.5%         | 6.2%          | 14.5%         |
|           | Injection             | Fluoroquinolones      | 14,764,825 450,340                | 95.0%         | 94.9%         | 97.7%         |
| Weaners   | Oral                 | Fluoroquinolones      | 207,658,150 1,143,175             | 450           | 450           | 450           |
|           | Oral                 | Polypeptides          | 452,000 100.0% 23                 | 100.0%        | 100.0%        | 100.0%        |
|           | Injection             | Aminoglycosides       | 8,654,000 4.2% 82,799              | 7.2%          | 10.1%         | 28.0%         |
|           | Injection             | Polypeptides          | 22,500 0.1% 23                   | 100.0%        | 100.0%        | 100.0%        |
|           | Injection             | Fluoroquinolones      | 22,500 0.1% 23                   | 100.0%        | 100.0%        | 100.0%        |
|           | Injection             | Polypeptides          | 229,500 2.0% 14,875               | 3.3%          | 2.3%          | 1.6%          |
|           | Injection             | Fluoroquinolones      | 14,764,825 450,340                | 95.0%         | 94.9%         | 97.7%         |
|           | Injection             | Polypeptides          | 14,764,825 450,340                | 95.0%         | 94.9%         | 97.7%         |
|           | Injection             | Aminoglycosides       | 12,500 0.1% 1,833                 | 0.5%          | 0.5%          | 0.4%          |
|           | Injection             | Polypeptides          | 12,500 0.1% 1,833                 | 0.5%          | 0.5%          | 0.4%          |
|           | Injection             | Fluoroquinolones      | 12,500 0.1% 1,833                 | 0.5%          | 0.5%          | 0.4%          |
|           | Injection             | Polypeptides          | 12,500 0.1% 1,833                 | 0.5%          | 0.5%          | 0.4%          |
|           | Injection             | Aminoglycosides       | 207,658,150 1,143,175             | 226,000       | 226,000       | 226,000       |
|           | Injection             | Polypeptides          | 207,658,150 1,143,175             | 100.0%        | 100.0%        | 100.0%        |

(Continued)
| Age group | Administration route | Antimicrobial classes | Amount of active ingredient in mg | DDDch (n) (%) | DDDvet (n) (%) | DCDch (n) (%) | DDDvet (n) (%) |
|-----------|----------------------|-----------------------|-------------------------------|----------------|----------------|----------------|----------------|
|          |                      | Polypeptides          | 22,934,400                    | 318,533        | 382,240        | 31,853         | 40,664         |
|          |                      | 11.5%                 |                               | 48.4%          | 29.2%          | 37.8%          |
| Finisher pigs | Injection | Sulfonamides        | 91,210,000                    | 200,556        | 82,818         | 20,056         | 26,120         |
|          |                      | 45.8%                 |                               | 10.5%          | 18.4%          | 24.3%          |
|          |                      | Tetracyclins         | 62,715,000                    | 229,167        | 166,589        | 22,099         | 22,723         |
|          |                      | 31.5%                 |                               | 21.6%          | 21.4%          | 21.1%          |
|          |                      | Injection             | 36,317,845                    | 122,493        | 40,894         | 27,566         |
|          |                      | Polypeptides          | 22,934,400                    | 382,240        | 318,533        | 40,664         |
|          |                      | 11.5%                 |                               | 48.4%          | 29.2%          | 37.8%          |
|          |                      | Sulfonamides        | 91,210,000                    | 200,556        | 82,818         | 20,056         | 26,120         |
|          |                      | 45.8%                 |                               | 10.5%          | 18.4%          | 24.3%          |
|          |                      | Tetracyclins         | 62,715,000                    | 229,167        | 166,589        | 22,099         | 22,723         |
|          |                      | 31.5%                 |                               | 21.6%          | 21.4%          | 21.1%          |
|          |                      | Injection             | 36,317,845                    | 122,493        | 40,894         | 27,566         |
|          |                      | Polypeptides          | 22,934,400                    | 382,240        | 318,533        | 40,664         |
|          |                      | 11.5%                 |                               | 48.4%          | 29.2%          | 37.8%          |
|          |                      | Sulfonamides        | 91,210,000                    | 200,556        | 82,818         | 20,056         | 26,120         |
|          |                      | 45.8%                 |                               | 10.5%          | 18.4%          | 24.3%          |
|          |                      | Tetracyclins         | 62,715,000                    | 229,167        | 166,589        | 22,099         | 22,723         |
|          |                      | 31.5%                 |                               | 21.6%          | 21.4%          | 21.1%          |
|          |                      | Injection             | 36,317,845                    | 122,493        | 40,894         | 27,566         |
|          |                      | Polypeptides          | 22,934,400                    | 382,240        | 318,533        | 40,664         |
|          |                      | 11.5%                 |                               | 48.4%          | 29.2%          | 37.8%          |
|          |                      | Sulfonamides        | 91,210,000                    | 200,556        | 82,818         | 20,056         | 26,120         |
|          |                      | 45.8%                 |                               | 10.5%          | 18.4%          | 24.3%          |
|          |                      | Tetracyclins         | 62,715,000                    | 229,167        | 166,589        | 22,099         | 22,723         |
|          |                      | 31.5%                 |                               | 21.6%          | 21.4%          | 21.1%          |
|          |                      | Injection             | 36,317,845                    | 122,493        | 40,894         | 27,566         |

Numbers in bold are mentioned in the results part of the study.

1DDCh: Number of treatment days based on Swiss Defined Daily Doses.
2DDvet: Number of treatment days based on Defined Daily Doses of the European Medicine Agency (EMA).
3DCDch: Number of treatments based on Swiss Defined Course Doses.
4DCDvet: Number of treatments based on Defined Course Doses of the European Medicine Agency (EMA).
Echtermann et al. AMU on Swiss Pig Farms

FIGURE 2 | Scatterplots of defined daily doses (DDD) and defined course doses (DCD) at the farm level calculated either by Swiss values (DDCh/farm and DCDCh/farm). Each dataset was tested for normality by Shapiro-Wilk test and for all datasets the null hypothesis was rejected (each P < 0.001). So non-normal distributed data was concluded and the correlation was investigated by Spearman’s rho test.

TABLE 4 | Median values of the defined daily doses (DDD) and defined course doses (DCD) based on the number of Switzerland (DDCh/farm and DCDCh/farm) and the European Medicine Agency (DDDvet/farm and DCDvet/farm) for the different type of farms (farrow-to-finish farm, finishing farm and piglet-producing farm).

|                | DDCh/farm | DDDvet/farm | DCDCh/farm | DCDvet/farm |
|----------------|-----------|-------------|------------|-------------|
| 1) Farrow-to-finish farm | 4.40 (0.67–16.02) | 3.63 (0.83–15.46) | 1.43 (0.27–4.48) | 0.98 (0.239–3.63) |
| 2) Finishing farm | 0.27* (0–3.82) | 0.26* (0–2.75) | 0.08* (0–0.70) | 0.077* (0–0.50) |
| 3) Piglet-producing farm | 4.88 (0.96–12.45) | 3.99 (1.04–12.04) | 1.22 (0.29–4.61) | 1.05 (0.26–2.65) |

10 and 90% percentiles are given in brackets. Each dataset was tested for normality by Shapiro-Wilk tests and for all datasets the null hypothesis was rejected (each P < 0.001). So non-normal distributed data was concluded. By performing Kruskal-Wallis test for independent samples and post hoc pairwise analysis (Bonferroni correction) significant differences between finishing farm and farrow-to-finish-farm respectively, piglet-producing farm could be observed (each P < 0.001). No significant differences between farrow-to-finishing farm and piglet-producing farm could be observed (each P > 0.05).

the participation in the present study and supply of data was voluntary, some bias cannot be completely ruled out due to the fact that knowledge and motivation of farmers have an influence on AMU (24). We consider the coverage of the study population to be adequate for our study goals with 3.3% of all Swiss pig farms and 9.5% of all sows, and it allows to deduce that especially larger farms seemed to be more motivated to participate in the study.

Since the data underlying this study did not include a record about the length of pigs’ stay in the farrowing unit, the nursery unit and the fattening unit, it is not feasible to make an exact evaluation of how many theoretical treatment days or treatments would be possible in the life span of a pig, as calculated by Timmermann et al. (25). However, the calculation behind the number of dosages on farm level is based on the population of animals present or produced during 1 year and this makes it comparable to other systems using defined doses to estimate AMU per farm in livestock (11–13).

Since the present study is based on calculations from prescribed amounts, the exact amounts of antimicrobials used by the farmer cannot be assessed and overdosing as well as underdosing could bias the results and the study only allows a statistical estimation of the probable AMU.

Another aspect of this study which is shown in Table 1 is the different evaluation of monitoring systems based either on the measurement of the amount of active ingredient or on the measurement of application equivalents such as defined doses: due to the lower standard weight of piglets, a considerable number of defined treatments can be performed with an amount of antimicrobial suitable for a single treatment of just one sow. As a consequence, the observed amount of active ingredients for e.g., piglets was low whereas the number of calculated doses was high. This is in line with prior studies (26) and EMA advice cautioning that differences in dosing between species and substances must be taken into account when using DDD and DCD values (19).
FIGURE 3 | Comparison of antimicrobial use in different types of farms (farrow-to-finish farms, finishing farms and piglet-producing farms) measured by the number of defined daily doses (DDD) and defined course doses (DCD) per farm based on the values of Switzerland (DDDch/farm and DCDch/farm) and the European Medicine Agency (DDDvet/farm and DCDvet/farm). Each dataset was tested for normality by Shapiro-Wilk test and for all datasets the null hypothesis was rejected (each $P < 0.001$). So non-normal distributed data was concluded. By performing Kruskal-Wallis test for independent samples and post hoc pairwise analysis (Bonferroni correction) significant differences between finishing farm and farrow-to-finish-farm respectively, piglet-producing farm could be observed (each $P < 0.001$). No significant differences between farrow-to-finishing farm and piglet-producing farm could be observed (each $P > 0.05$).

In general, a low value for a defined dose results in a higher number of calculated or estimated doses in a population (17). This explains some differences between the number of DDDch or DCDch on the one side and DDDvet and DCDvet on the other side. For example, macrolides showed a difference in calculated use depending on whether Swiss or European definitions were chosen. As a previous study showed, there are six Swiss premix products containing the macrolide tylosin with much lower defined daily and course doses compared to the values of the EMA (20), thus explaining the relatively high number of DDDch and DCDch in this category. This general understanding can also be used to explain the results in Table 1. All groups with a high ratio between the calculation based on Swiss or European definitions come by a frequent use with approvals whose DDDch and DCDch values differ strongly from the DDDvet and DCDvet values.

In accordance with a recently published study, the animal groups with the highest numbers of treatment days and total number of treatments observed were weaners (DDDch, DDDvet, and DCDvet) and piglets (DCDch) (27). These groups are most susceptible to bacterial infections and, at least for the weaners, frequent group therapies at weaning can be assumed, which is reflected in the high proportion of treatments with premixes, as described by other studies (28). This assumption is also underlined by the fact, that a longer Swiss treatment duration could be observed only for weaned piglets and for premixes and a relationship between both findings could be hypothesized. Thus, young age groups should already be considered in terms of resistance prevention and the use of group therapies by premixes in feed in these groups should be critically re-evaluated (29).

Furthermore, when calculating the number of DDSs, relatively high use could be observed for premixes and in contrast, a relatively high total number of course doses could be observed for injections in this study. This can be explained by the comparison of treatment durations between injections and premixes, since the number of calculated course doses decreases with the increase in treatment duration of the premixes. Previous publications confirmed the high proportion of premixes used in the pig sector in Switzerland (30,31). An increased risk of development of resistance for specific active substances and bacteria is documented by this administration route (32). Thus, group therapies should be reduced to the necessary minimum.
A relatively high proportion of treatments with Highest Priority Critically Important Antimicrobials (HPCIA)s could be observed in this study (e.g., 44.8% of DDDvet’s). These findings are comparable to results recently published from the EFFORT consortium (27), but varying from results of a previous study, where a lower AMU quantification of HPCIA[s] for pigs in Switzerland based on total amount of given active ingredient was observed (33). Due to the documented spread of resistance genes e.g., against fluorquinolones in the pig sector (34), every use of these substances should be of concern and further research investigating restriction of indications and potential reductions in usage is needed.

The results from the different farm types show again that the younger age groups are most frequently treated. Both, farrow-to-finishing farm as well as piglet-producing farms in contrast to the finishing farms keep the high consumption age groups of piglets and weaners. This could explain the significant difference. Due to the small number of calculated defined doses of finisher pigs, no significant difference between farrow-to-finishing and piglet-producing farms was observed.

In order to gain a better understanding of the differences between these individual farms, further studies are needed to examine the role of the farmer (23) as well as AMU quantification and performance data (35).

CONCLUSION

In summary, this study demonstrated a general association of the AMU systems at the farm level, nevertheless, differences were seen in detail according to whether the calculation was based on individual Swiss or average European values. The benefit of the European values for internationally comparative AMU monitoring is undisputed, but for a detailed evaluation, Swiss definitions could be more accurate as they are based on the specific approvals of the country. This must be considered in order to understand international AMU comparisons in the future. The study also highlighted the need to further evaluation for the use of HPCIA[s].

REFERENCES

1. Chantziaras I, Boyen E, Callens B, Dewulf J. Correlation between veterinary antimicrobial use and antimicrobial resistance in food-producing animals: a report on seven countries. J Antimicrob Chemother. (2014) 69:827–34. doi: 10.1093/jac/dkt443
2. Ungemach FR. Einsatz von Antibiotika in der Veterinärmedizin: Konsequenzen und rationaler Umgang. Tierarzt Prax. (1999) 1999:335–40.
3. Aarestrup FM. Veterinary drug usage and antimicrobial resistance in bacteria of animal origin. Basic Clin Pharmacol Toxicol. (2005) 96:271–81. doi: 10.1111/j.1742-7843.2005.pto9601.x
4. da Costa PM, Loureiro L, Matos AJ. Transfer of multidrug-resistant bacteria between intermingled ecological niches: the interface between humans, animals and the environment. Int J Environ Res Public Health. (2013) 10:278–94. doi: 10.3390/ijerph10010278
5. Mølbak K. Spread of resistant bacteria and resistance genes from animals to humans - The public health consequences. J. Vet. Med. B Infect. Dis. Vet. Public Health. (2004) 51:364–9. doi: 10.1111/j.1439-0450.2004.00788.x
6. Ungemach FR, Müller-Bahrdt D, Abraham G. Guidelines for prudent use of antimicrobials and their implications on antibiotic usage in veterinary medicine. Int J Med Microbiol. (2006) 296(Suppl. 41):33–8. doi: 10.1016/j.jmm.2006.01.059
7. World Health Organization. Global Action Plan on Antimicrobial Resistance. (2015). Available online at: http://www.wpro.who.int/entity/drug_resistance/resources/global_action_plan_eng.pdf (accessed February 04, 2019).
8. Schweizerische Eidgenossenschaft. Strategie Antibiotikaresistenzen Schweiz (StAR). (2015). Available from: https://www.bundespublikationen.admin.ch/chop_mimes_bbl/2G/2C59E545D7371EE5A7B0EF1D8BC8BB01.pdf (accessed February 04, 2019).
9. Eidgenössisches Department des Innern EDI. ARCH-Vet, Bericht über den Vertrieb von Antibiotika in der Veterinärmedizin in der Schweiz 2017. (2018). Available online at: https://www.newsdl.admin.ch/newsdl/message/attachments/52863.pdf (accessed February 04, 2019).
10. European Medicines Agency, EMA. Sales of Veterinary Antimicrobial Agents in 30 European Countries in 2015. (2017). Available online at: https://www.ema.europa.eu/documents/report/seventh-esvac-report-

DATA AVAILABILITY

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

Since this was only data that had no influence on the actual treatment of the animals, an animal welfare permit was not required. No manipulations or something similar were carried out on any animals.

AUTHOR CONTRIBUTIONS

DK, XS, CM, and TE contributed conception and design of the study. TE organized the database and performed the statistical analysis. CM is responsible for the correctness of the pharmacological formulations and the part in the manuscript about measurement methodologies. TE wrote the first draft of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING

This work was partially funded by the Swiss Swine Health Service (SSHs).

ACKNOWLEDGMENTS

The authors would like to thank the members of the Swiss Swine Health Service for their support with the data collection on farms and Emily Katharina Gueldner for her help in proofreading of this work.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fvets.2019.00240/full#supplementary-material
sales-veterinary-antimicrobial-agents-30-european-countries-2015_en.pdf (accessed February 04, 2019).
11. Wageningen Bioveterinary Research. MARAN 2018 Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands in 2017. (2018). Available online at: https://www.wur.nl/upload_mm/7b/0/5e586949-61f4-420e-a2ca-ac9ca56f016_Maran%202018.pdf (accessed February 04, 2019).
12. Statens Serum Institut National Veterinary Institute, Technical University of Denmark National Food Institute, Technical University of Denmark. DANMAP 2017 - Use of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria From Food Animals, Food and Humans in Denmark. (2018). Available online at: https://www.danmap.org/-/media/arkiv/projektsites/danmap/danmap-reports/danmap-2017/danmap2017.pdf;la=en (accessed February 04, 2019).
13. Norwegian Food Safety Authority, Norwegian Veterinary Institute. NORM/NORM-VET 2017. Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. (2018). Available online at: https://unn.no/Documents/Kompetansetjenester,%20sentre%20og%20fagräid/NORM%20-%20Norsks%20overvåkingsystem%20for%20antibiotikaresistens%20hos%20domkrober/Rapporten/NORM_NORM_VET_2017.pdf (accessed February 04, 2019).
14. Merlo J, Wessling A, Melander A. Comparison of dose standard units: Definition and General Considerations. Eur J Clin Pharmacol. (1996) 50:27–30. doi:10.1007/BF022800064
15. Collinæu L, Belloc C, Stark KD, Hémonic A, Postma M, Dewulf J, et al. Guidance on the Selection of Appropriate Indicators for Quantification of Antimicrobial Usage in Humans and Animals. Zoonoses Public Health. (2017) 64:165–84. doi:10.1111/zph.12298
16. World Health Organization. Definition and General Considerations. (2018). Available online at: https://www.whocc.no/ddd/definition_and_general_considera/ (accessed May 29, 2019).
17. Postma M, Sjölund M, Collinæu L, Löskén S, Stark KD, Dewulf J. Assigning defined daily doses animal: a European multi-country experience for antimicrobial products authorized for usage in pigs. J Antimicrob Chemother. (2015) 70:294–302. doi:10.1093/jac/dku347
18. European Medicines Agency, EMA. Defined Daily Doses for Animals (DDDvet) and Defined Course Doses for Animals (DCDvet). (2016). Available online at: https://www.ema.europa.eu/documents/other/defined-daily-doses-animals-dddvet-defined-course-doses-animals-dcdvet-european-surveillance_en.pdf (accessed February 04, 2019).
19. European Medicines Agency, EMA. Principles on Assignment of Defined Daily Dose for Animals (DDDvet) and Defined Course Dose for Animals (DCDvet). (2015). Available online at: https://www.ema.europa.eu/documents/scientific-guide/principles-assignment-defined-daily-dose-animals-dddvet-defined-course-doses-animals-dcdvet_en.pdf (accessed February 04, 2019).
20. Echtermann T, Müntener CR, Torgerson PR, Sidler X, Kümmerlen D. Etablierung von definierten Tages-dosierungen und definierten Gesamt-behandlungsdosierungen zur Messung des Antibiotikaverbrauchs in der Schweizer Schweineproduktion. Schweiz Arch Tierheilkd. (2016) 160:597–605. doi:10.17236/sat00179
21. Eidgenössisches Departement des Innern, Bundesamt für Statistik. Landwirtschaftliche Strukturveränderung. 2018 (2019). Available online at: http://www.bfs.admin.ch/bfs/de/home/statistiken/landforstwirtschaft/landwirtschaft.gnpdetail.2019-0444.html (accessed May 29, 2019).
22. European Surveillance of Veterinary Antimicrobial Consumption, ESVAC. Revised ESVAC Reflection Paper on Collecting Data on Consumption of Antimicrobial Agents Per Animal Species, on Technical Units of Measurement and Indicators for Reporting Consumption of Antimicrobial Agents in Animals. (2013). Available online at: https://www.ema.europa.eu/documents/scientific-guide/revised-european-surveillance-veterinary-antimicrobial-consumption-esvac-reflection-paper-collecting_en.pdf (accessed February 04, 2019).
23. Institute of Pharmacology and Toxicology Vetsuisse Faculty. Tierarzneimittelkompendium der Schweiz. Available online at: www.tierarzneimittel.ch (accessed May 29, 2019).
24. Visschers VH, Postma M, Sjölund M, Bachhans A, Collinæu L, Lœsken S, et al. Higher perceived risk of antimicrobials is related to lower antimicrobial usage among pig farmers in four European countries. Vet Rec. (2016) 179:490. doi:10.1136/vr.103844
25. Timmerman T, Dewulf J, Catry B, Feyen B, Opsomer G, Kruif A de, et al. Quantification and evaluation of antimicrobial drug use in group treatments for fattening pigs in Belgium. Prev Vet Med. (2006) 74:251–63. doi:10.1016/j.prevetmed.2005.10.003
26. Jensen VF, Jacobsen E, Bager F. Veterinary antimicrobial-usage statistics based on standardized measures of dosage. Prev Vet Med. (2004) 64:201–15. doi:10.1016/j.prevetmed.2004.04.001
27. Sarrazin S, Joosten P, van Gompel L, Luiken RE, Menvaer JA, et al. Quantitative and qualitative analysis of antimicrobial usage patterns in 180 selected farrow-to-finish pig farms from nine European countries based on single batch and purchase data. J Antimicrob Chemother. (2018) 74:807–16. doi:10.1093/jac/dky503
28. Sjölund M, Postma M, Collinæu L, Löskén S, Bachhans A, Belloc C, et al. Quantitative and qualitative antimicrobial usage patterns in farrow-to-finish pig herds in Belgium, France, Germany and Sweden. Prev Vet Med. (2016) 130:41–50. doi:10.1016/j.prevetmed.2016.06.003
29. Diana A, Manzanilla EC, Calderón Díaz JA, Leonard FC, Boyle LA. Do weaner pigs need in-feed antibiotics to ensure good health and welfare? PLoS ONE. (2017) 12:e0185622. doi:10.1371/journal.pone.0185622
30. Arnold S, Gassner B, Giger T, Zwahlen R. Banning antimicrobial growth promoters in feedstuffs does not result in increased therapeutic use of antibiotics in medicated feed in pig farming. Pharmacoepidemiol Drug Saf. (2003) 13:323–31. doi:10.1002/pds.874
31. Müntener RC, Stebler R, Horisberger U, Althaus RF, Gassner B. Berechnung der Therapienäheits bei Ferkeln und Mastschweinen beim Einsatz von Antibiotika in Fütterungsarzneimitteln. Schweiz Arch Tierheilkd. (2013) 155:365–72. doi:10.1024/0036-7281/a000472
32. Wiuff C, Lykkesfeldt J, Svendsen O, Aarestrup FM. The effects of oral and intramuscular administration and dose escalation of enrofloxacin on the selection of quinolone resistance among Salmonella and coliforms in pigs. Res Vet Sci. (2003) 75:185–93. doi:10.1016/S0034-5288(03)00112-7
33. Regula G, Torriani K, Gassner B, Stucki F, Müntener CR. Prescription patterns of antimicrobials in veterinary practices in Switzerland. J Antimicrob Chemother. (2009) 63:805–11. doi:10.1093/jac/dkp009
34. Römer A, Scherz G, Reupke S, Meißner J, Wallmann J, Kietzmann M, et al. Effects of intramuscularly administered enrofloxacin on the susceptibility of commensal intestinal Escherichia coli in pigs (suis scrfa domestica). BMC Vet Res. (2017) 13:378. doi:10.1186/s12917-017-1260-8
35. Collinæu L, Bachhans A, Dewulf J, Emanuelsson U, Grosse Beilage E, Lehebel A, et al. Profile of pig farms combining high performance and low antimicrobial usage within four European countries. Vet Rec. (2017) 181:657. doi:10.1136/vr.103988

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling Editor declared a past co-authorship with one of the authors CM.